Sanofi‘s patent provides methods for screening, diagnosing, and treating acid sphingomyelinase disorders like Niemann-Pick disease. The claim outlines a method for treating acid sphingomyelinase deficiency in humans using recombinant human acid sphingomyelinase. The treatment involves administering increasing doses intravenously and measuring lyso-sphingomyelin levels in biological samples. GlobalData’s report on Sanofi gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sanofi, NSAID cancer drugs was a key innovation area identified from patents. Sanofi's grant share as of May 2024 was 60%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of acid sphingomyelinase deficiency using enzyme replacement therapy
A recently granted patent (Publication Number: US11998592B2) discloses a method for treating acid sphingomyelinase deficiency in human subjects. The method involves administering recombinant human acid sphingomyelinase (rhASM) intravenously at increasing doses from 0.03 or 0.1 mg/kg to 3 mg/kg, followed by maintenance doses of 3 mg/kg or less. The levels of lyso-sphingomyelin (lyso-SPM) in biological samples collected within specific time frames after each dose are measured, with each dose administered two weeks apart.
Furthermore, the method includes administering maintenance doses at 1, 2, or 3 mg/kg, particularly in subjects with elevated lyso-SPM levels compared to healthy controls. The biological samples for measuring lyso-SPM levels can be collected as dried blood spots and are obtained before each subsequent dose is administered. This patent provides a structured approach to treating acid sphingomyelinase deficiency, offering a clear dosing regimen and monitoring strategy to assess the effectiveness of the treatment over time.
To know more about GlobalData’s detailed insights on Sanofi, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
